Gene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug ...

The potential use of allogeneic induced pluripotent stem cell (iPSC)-derived T cells ... to be the next standard for cancer immune-cell therapy. In 2021, Kaneko’s group produced iPS-Ts from ...

Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on ...